GHK-Cu vs P-21 Peptide
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
GHK-Cu
GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. It plays a role in wound healing, skin regeneration, and anti-inflammatory signaling. Levels decline significantly with age, which has driven interest in topical and injectable supplementation.
Full profileP-21 Peptide
Short neuropeptide based on the activity-dependent neurotrophic factor (ADNF) family with potent neuroprotective effects demonstrated in Alzheimer's disease models. Distinct from the cell cycle inhibitor protein p21/CDKN1A. Reduces amyloid-beta burden, improves cognitive outcomes in rodent models, and modulates neuroinflammation through STAT3 and JAK2 signaling pathways.
Full profile| GHK-Cu | P-21 Peptide | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | Copper Peptide GHK-Cu, Glycyl-L-histidyl-L-lysine copper, Copper Tripeptide-1 | P21, Colivelin fragment, P21 neuropeptide, ADNF-related neuropeptide |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 1mg–3mg mg, daily to every other day (injectable); twice daily (topical) | 5mcg–20mcg mcg, daily or every other day (intranasal or SC) |
| Administration | Subcutaneous injection, Topical application (cream, serum — most common consumer use), Intradermal injection (skincare clinics) | Intranasal, Subcutaneous injection |
| Key side effects | Injection site redness (transient), Mild skin irritation with topical (typically resolves with reduced frequency), Rarely reported: metallic taste (with injectable use at higher doses) | Limited human safety data, In animal studies: well-tolerated at therapeutic doses, Theoretical STAT3 pathway concerns with chronic use (pro-survival signaling), Nasal irritation (intranasal route) |
| Cited sources | 4 references | 2 references |
Key differences
- Evidence level differs: GHK-Cu is research-stage, while P-21 Peptide is preclinical only.
- Administration: GHK-Cu — Subcutaneous injection, Topical application (cream, serum — most common consumer use), Intradermal injection (skincare clinics); P-21 Peptide — Intranasal, Subcutaneous injection.
- Dosing units differ: GHK-Cu is dosed in mg, P-21 Peptide in mcg — they operate at different scales.
- Frequency: GHK-Cu is typically daily to every other day (injectable); twice daily (topical); P-21 Peptide is daily or every other day (intranasal or SC).
- Research depth: this profile cites 4 sources for GHK-Cu vs 2 for P-21 Peptide.
How each works
GHK-Cu
GHK-Cu has been studied for its ability to stimulate collagen, elastin, and glycosaminoglycan synthesis, promote wound healing, and exhibit antioxidant and anti-inflammatory effects. Gene-expression work by Pickart and colleagues found GHK altered expression (>50% up or down) in roughly 32% of assayed human genes — the basis of the widely-cited '~4,000 genes' figure. Its evidence is strongest for in-vitro and topical/cosmetic use; robust human trials of injectable/systemic GHK-Cu are lacking.
P-21 Peptide
P-21 activates STAT3/JAK2 signaling through CNTF-related pathways, reducing amyloid-beta toxicity by activating amyloid-clearing enzymes (insulin-degrading enzyme, neprilysin) and inhibiting tau phosphorylation. Derived from the colivelin family of neuroprotective peptides, P-21 demonstrates cognitive improvement in Alzheimer's mouse models at doses far below cytotoxic levels. Human data remains limited.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.